Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
81,089,428
-
Shares change
-
+40,263,309
-
Total reported value, excl. options
-
$448,181,562
-
Value change
-
+$214,692,780
-
Put/Call ratio
-
28.8%
-
Number of buys
-
116
-
Number of sells
-
-38
-
Price
-
$5.53
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2018
180 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2018.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81,089,428 shares
of 236,234,693 outstanding shares and own 34.3% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (24,471,453 shares), BlackRock Inc. (8,296,405 shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5,656,462 shares), Nantahala Capital Management, LLC (5,064,089 shares), Vanguard Group Inc (4,907,351 shares), Novo Holdings A/S (3,100,000 shares), STATE STREET CORP (2,637,846 shares), PERCEPTIVE ADVISORS LLC (1,703,440 shares), CITADEL ADVISORS LLC (1,439,742 shares), and RICE HALL JAMES & ASSOCIATES, LLC (1,221,498 shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.